# TNFR1 signaling is positively regulated by Jak-2 and c-Src via tyrosine phosphorylation

**Authors:** Fatma Zehra HAPİL ZEVKLİLER, Fatma Ece ÇOPUROĞLU, Mustafa Gökhan ERTOSUN, Ufuk MERT, Derya ÖZEŞ, Osman Nidai ÖZEŞ

PMC · DOI: 10.55730/1300-0152.2677 · 2023-11-06

## TL;DR

This paper shows that TNFR1 is activated through tyrosine phosphorylation by JAK2 and c-Src, leading to ERK and Akt signaling.

## Contribution

The study identifies JAK2 and c-Src as key regulators of TNFR1 tyrosine phosphorylation, revealing a new noncanonical signaling pathway.

## Key findings

- TNFR1 is phosphorylated at Y360 by c-Src and Y401 by JAK2.
- Phosphorylation of Y360 and Y401 enhances Grb2 and PI3Kp85 interactions with TNFR1.
- Phosphomimetic mutations at Y360D and Y401D increase ERK and Akt activation.

## Abstract

Tumor necrosis factor alpha (TNFα, a.k.a. TNF) is a pleiotropic cytokine that exerts most of its effects through type 1 TNF receptor (TNFR1). Following TNF binding, TNFR1 recruits TRADD (tumor necrosis factor receptor type 1-associated DEATH domain). This interaction triggers formation of signalosome complexes which have been claimed to induce apoptosis (via downstream caspase activations), inflammation (via NF-kappaB) and stress pathways (JNK & p38). However, the mechanism underlying TNF-induced ERK and AKT activation is not completely revealed. TNFR1 is known to constitutively bind c-Src and JAK2, and these enzymes were previously demonstrated to modulate TNF signaling. Therefore, we hypothesized that TNFR1 could be tyrosine phosphorylated by JAK2 and/or c-Src and TNF-induced ERK and Akt activation may be mediated by this phosphorylation.

Site-directed mutagenesis (SDM) was performed to substitute the two putative Tyrosine phosphorylation sites on TNFR1 (Y360 and Y401) with alanine (A) or with aspartic acid (D), to inhibit or mimic constitutive phosphorylation, respectively. In 293T cells transfected with mutated or wild type TNFR1, ERK and Akt activations were determined by western blot. TNFR1 interaction with c-Src, JAK2, p85 and Grb2 was examined by co-IP. NF-kB activation was measured by luciferase assay, while proliferation was measured by MTT and apoptosis was evaluated by colorimetric caspase 8/3 assays. For determination of necrosis rates, cellular DNA fragmentation ELISA was performed.

In this report, we show that TNFR1 is phosphorylated by JAK2 tyrosine kinase at Y401 and by c-Src at Y360 and Y401. Phosphorylation of Y360 and Y401 augments the interaction of Grb2 and PI3Kp85 with TNFR1. We also demonstrate that phosphomimetic mutations of Y360D and Y401D enhance ERK and Akt activation.

TNFR1 is tyrosine phosphorylated by both c-Src and JAK2, triggering a “noncanonical” pathway, that activates ERK and Akt.

## Linked entities

- **Genes:** TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132], TRADD (TNFRSF1A associated via death domain) [NCBI Gene 8717], EPHB2 (EPH receptor B2) [NCBI Gene 2048], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], JAK2 (Janus kinase 2) [NCBI Gene 3717], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714], GRB2 (growth factor receptor bound protein 2) [NCBI Gene 2885], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Proteins:** TNF (tumor necrosis factor), TRADD (TNFRSF1A associated via death domain), EPHB2 (EPH receptor B2), AKT1 (AKT serine/threonine kinase 1), JAK2 (Janus kinase 2), SRC (SRC proto-oncogene, non-receptor tyrosine kinase), GRB2 (growth factor receptor bound protein 2), NFKB1 (nuclear factor kappa B subunit 1)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, GRB2 (growth factor receptor bound protein 2) [NCBI Gene 2885] {aka ASH, EGFRBP-GRB2, Grb3-3, MST084, MSTP084, NCKAP2}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, TRADD (TNFRSF1A associated via death domain) [NCBI Gene 8717] {aka Hs.89862}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** inflammation (MESH:D007249), necrosis (MESH:D009336)
- **Mutations:** Y401, Y401D, Y360, Y360D
- **Cell lines:** 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11042867/full.md

---
Source: https://tomesphere.com/paper/PMC11042867